JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Integra LifeSciences (NASDAQ:IART) Stock

Integra LifeSciences (NASDAQ:IART) had its price objective lifted by equities research analysts at JPMorgan Chase & Co. from $12.00 to $13.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an “underweight” rating on the life sciences company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 8.24% from the company’s previous close.

Several other brokerages also recently commented on IART. Truist Financial set a $15.00 target price on shares of Integra LifeSciences and gave the stock a “hold” rating in a report on Wednesday, October 15th. Citigroup reiterated a “sell” rating and issued a $12.00 target price (up previously from $10.00) on shares of Integra LifeSciences in a report on Tuesday, October 7th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Integra LifeSciences in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $16.17.

Integra LifeSciences Stock Up 1.7%

IART stock opened at $12.01 on Friday. The company has a current ratio of 1.23, a quick ratio of 0.73 and a debt-to-equity ratio of 1.18. Integra LifeSciences has a 1 year low of $11.05 and a 1 year high of $27.13. The company has a fifty day simple moving average of $14.70 and a 200 day simple moving average of $13.81. The firm has a market cap of $935.71 million, a PE ratio of -1.84 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Thursday, October 30th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.11. The business had revenue of $402.06 million during the quarter, compared to analyst estimates of $414.31 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. Integra LifeSciences’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.41 EPS. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS. FY 2025 guidance at 2.190-2.240 EPS. Sell-side analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its position in shares of Integra LifeSciences by 55.3% during the 3rd quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 913 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Integra LifeSciences by 205.9% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company’s stock valued at $38,000 after acquiring an additional 2,108 shares in the last quarter. Osaic Holdings Inc. boosted its position in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after acquiring an additional 1,104 shares in the last quarter. AlphaQuest LLC acquired a new stake in shares of Integra LifeSciences during the 2nd quarter valued at about $73,000. Finally, EMC Capital Management acquired a new stake in shares of Integra LifeSciences during the 2nd quarter valued at about $75,000. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.